|
ValiRx PLC on Tuesday announced its establishment of a new wholly-owned subsidiary, and plans to file new patents for Val201. Shares in the Essex-based life sciences company were 2.1% higher at 0.54 pence on Tuesday in London. ValiRx said the new subsidiary, Blue Ribbon Bio Ltd, has been incorporated to house all its prostate cancer-associated assets. This initially consists of existing intellectual property for Val201. ValiRx, which is focused on early-stage cancer therapeutics and on women’s health, said it plans to file new application-based patents for Val201. These will be held by Blue Ribbon. It said a notice of allowance has been received for a Canadian ’Medical Use’ patent, for the treatment of non-cancerous conditions relating to the use of the Val201 peptide in endometriosis. ‘A detailed technical and market assessment has been conducted for Val201 as part of a comprehensive review of ValiRx’s current and potential assets and concluded that there is still a strong rationale for Val201 within the treatment pathway for prostate cancer,’ the company said. ‘A critical path plan to expedite validation of improvements to Val201 to create additional value, extend patent coverage and position for partnering is now in place.’ Chief Executive Officer Mark Eccleston commented: ‘We have an opportunity to build a broader prostate cancer-focused portfolio based on current and future pan-cancer assets that can be applied in this indication. ‘Having worked on the original pre-clinical development of Val201, I am pleased that there is still a market opportunity for this asset, and we intend to rapidly complete the planned work required to get this back into the clinic in new and improved form.’ He added: ‘Several of our current assets, those in our repurposing program with Dominion and other assets under consideration for evaluation and in-licensing, can be applied across various stages of prostate cancer as well as our core focus in women’s health. ‘By ringfencing these assets in a portfolio approach we believe that we can create significant value and attract partners for clinical development.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
